NO20043576L - Pharmaceutical formulation comprising melatonin - Google Patents

Pharmaceutical formulation comprising melatonin

Info

Publication number
NO20043576L
NO20043576L NO20043576A NO20043576A NO20043576L NO 20043576 L NO20043576 L NO 20043576L NO 20043576 A NO20043576 A NO 20043576A NO 20043576 A NO20043576 A NO 20043576A NO 20043576 L NO20043576 L NO 20043576L
Authority
NO
Norway
Prior art keywords
melatonin
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
NO20043576A
Other languages
English (en)
Other versions
NO332525B1 (no
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20043576(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of NO20043576L publication Critical patent/NO20043576L/no
Publication of NO332525B1 publication Critical patent/NO332525B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
NO20043576A 2002-04-28 2004-08-27 Farmasoytisk formulering omfattende melatonin NO332525B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PCT/IL2003/000240 WO2003086352A1 (en) 2002-04-08 2003-03-20 Pharmaceutical formulation comprising melatonin

Publications (2)

Publication Number Publication Date
NO20043576L true NO20043576L (no) 2004-12-22
NO332525B1 NO332525B1 (no) 2012-10-08

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043576A NO332525B1 (no) 2002-04-28 2004-08-27 Farmasoytisk formulering omfattende melatonin

Country Status (30)

Country Link
US (1) US20050175692A1 (no)
EP (1) EP1494650B1 (no)
JP (1) JP2005527583A (no)
KR (1) KR101000624B1 (no)
CN (1) CN100386070C (no)
AR (1) AR039232A1 (no)
AT (1) ATE507831T1 (no)
AU (1) AU2003227304B2 (no)
BR (1) BR0308762A (no)
CA (1) CA2477516C (no)
DE (1) DE60336999D1 (no)
DK (1) DK1494650T3 (no)
EA (1) EA007954B1 (no)
ES (1) ES2366116T3 (no)
GT (1) GT200300064A (no)
HK (1) HK1075616A1 (no)
HN (1) HN2003000115A (no)
IL (1) IL149377A (no)
IS (1) IS2858B (no)
MX (1) MXPA04009893A (no)
NO (1) NO332525B1 (no)
NZ (1) NZ536298A (no)
PE (1) PE20040161A1 (no)
PL (1) PL209922B1 (no)
PT (1) PT1494650E (no)
TW (1) TW200305404A (no)
UA (1) UA86924C2 (no)
UY (1) UY27753A1 (no)
WO (1) WO2003086352A1 (no)
ZA (1) ZA200407563B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技(北京)有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (en) 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
MX2019004736A (es) 2016-10-31 2019-06-17 Neurim Pharma 1991 Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
CN100443480C (zh) * 1996-03-08 2008-12-17 武田药品工业株式会社 三环化合物及其制备和用途
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
WO1998002158A1 (en) 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
BR0009200A (pt) * 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
BR0308762A (pt) 2005-01-11
CN100386070C (zh) 2008-05-07
AU2003227304B2 (en) 2007-12-06
AU2003227304A2 (en) 2005-04-14
NZ536298A (en) 2008-09-26
US20050175692A1 (en) 2005-08-11
TW200305404A (en) 2003-11-01
CA2477516C (en) 2012-12-11
HN2003000115A (es) 2004-04-20
EP1494650B1 (en) 2011-05-04
WO2003086352A1 (en) 2003-10-23
EP1494650A1 (en) 2005-01-12
EP1494650A4 (en) 2006-07-12
KR20040101406A (ko) 2004-12-02
EA200401331A1 (ru) 2005-04-28
JP2005527583A (ja) 2005-09-15
IS7492A (is) 2004-10-07
UY27753A1 (es) 2003-05-30
GT200300064A (es) 2003-11-26
IL149377A0 (en) 2009-02-11
IL149377A (en) 2012-10-31
KR101000624B1 (ko) 2010-12-10
ATE507831T1 (de) 2011-05-15
CA2477516A1 (en) 2003-10-23
EA007954B1 (ru) 2007-02-27
UA86924C2 (ru) 2009-06-10
ZA200407563B (en) 2005-11-30
NO332525B1 (no) 2012-10-08
HK1075616A1 (en) 2005-12-23
PE20040161A1 (es) 2004-03-22
ES2366116T3 (es) 2011-10-17
CN1646098A (zh) 2005-07-27
MXPA04009893A (es) 2005-06-17
PT1494650E (pt) 2011-08-18
PL209922B1 (pl) 2011-11-30
AU2003227304A1 (en) 2003-10-27
DK1494650T3 (da) 2011-08-08
IS2858B (is) 2013-12-15
AR039232A1 (es) 2005-02-09
PL372867A1 (en) 2005-08-08
DE60336999D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
PT1501534E (pt) Formulacoes farmaceuticas
NO20033384D0 (no) Farmasöytisk formulering
DK3494995T3 (da) Superfin formoterolformulering
DK1545662T3 (da) Lægemiddelindgivelsessystem
NO20033785L (no) Farmasöytisk formulering
ATE380544T1 (de) Umhüllte feste darreichungsform
DK1620118T3 (da) Reversible pegylerede lægemidler
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DE602004017700D1 (de) Transmukosen verabreichung
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
NO20035627D0 (no) Farmasöytisk formulering
NO20050689L (no) Terapeutisk anvendelse
DK1596870T3 (da) Höjdosis-iblandronatformulering
NO20043576L (no) Pharmaceutical formulation comprising melatonin
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
ATA8202001A (de) Medikamentenapplikator
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
ITMI20020921A1 (it) Dispositivo per la sommistrazione di farmaci
NO20044164L (no) Farmasoytiske sammensetninger
DE50313285D1 (de) Melatonin-tagesdosierungseinheiten
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
SE0200449D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
MK1K Patent expired